RIPK3

Across TCGA pan-cancer cohorts, RIPK3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RIPK3 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RIPK3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RIPK3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

BRCA, LUSC, and LUAD are the cancer types where RIPK3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.136	0.579	<.001	30	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	6	view →
LUAD	OS	Median	III,IV	1.000	0.275	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RIPK3–BRCA (OS)

Open the BRCA breakdown →